

ALNYLAM PHARMACEUTICALS

Email: info@alnylam.com



Website: www.alnylam.com

PROFILE / DESCRIPTION of company:

Alnylam is developing an entirely new class of medicines based on the breakthrough discovery in biology known as RNA interference, or RNAi. Alnylam believes that RNAi therapeutics is a promising approach to silence disease-causing genes, and represent an opportunity to transform the treatment of many diseases.

BAYER

Website: <http://www.bayer.com>



PROFILE / DESCRIPTION of company:

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of healthcare and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com

Biotest AG

Email: coagulation@biotest.de



Website: www.biotest.com

PROFILE / DESCRIPTION of company:

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma, used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies e.g. in the indication of cancer of plasma cells which are produced by recombinant technologies.

CSL BEHRING

Phone: +49 69 305-8 44 37

Biotherapies for Life® **CSL Behring**

Website: www.cslbehring.com

PROFILE / DESCRIPTION of company:

CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies, which are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself.

Our commitment to improving the quality of life for people with serious and rare conditions is evident in everything we do. Whether we are manufacturing and marketing effective products or researching and developing innovative biotherapies, we are first and foremost focused on fulfilling our customers' needs.

LFB

Email: communication@lfb.fr

Phone: +33 1 69 82 70 10

Website: www.groupe-lfb.com



PROFILE / DESCRIPTION of company:

LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products indicated for the treatment of serious and often rare diseases in major therapeutic areas: hemostasis, immunology, intensive care and perinatal care. LFB Group is one of the leading European players specialized in biological medicinal products, and for the development and production of proteins and innovative treatments derived from biotechnologies. With 2,111 employees, the LFB group currently markets medicinal products in 40 countries throughout the world. <http://www.groupe-lfb.com>

Novo Nordisk Health Care AG

Email: cnld@novonordisk.com

Phone: +41 43 222 43 00

Website: www.novonordisk.com



PROFILE / DESCRIPTION of company:

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#)

Phone: +41 55 451 2121

Website: www.octapharma.com



PROFILE / DESCRIPTION of company:

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people's lives and has been doing so since 1983; because it's in our blood.

Octapharma employs approximately 6,400 people worldwide to support the treatment of patients in 105 countries with products across three therapeutic areas:

- Critical Care
- Haematology (coagulation disorders)
- Immunotherapy (immune disorders)

Octapharma owns five state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.

For more information visit www.octapharma.com

Email: alessandra.patella@pfizer.com

Phone: 0039 06 33182055

Website:

<http://www.pfizer.com/about>

<http://www.pfizer.com/health-and-wellness/health-topics/rare-diseases>



PROFILE / DESCRIPTION of company:

Pfizer Inc: Working Together for a Healthier World®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.

At Pfizer, we are also dedicated to delivering life-changing therapies that improve the lives of individuals affected by Rare Diseases and envision a day where many more diseases have treatment options. To that end, we have more than 20 approved medications as well as additional drugs currently in clinical trials.

F. Hoffmann-La Roche Ltd

Website: www.roche.com



PROFILE / DESCRIPTION of company:

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Shire

Email: shiredotcom@shire.com

Phone: +41 0 41 288 40 00

Website: www.shire.com



PROFILE / DESCRIPTION of company:

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products across our core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal/Internal Medicine/Endocrine, Hereditary Angioedema, and Oncology.

Sobi

Email: Morten.Gron@sobi.com

Phone: +45 25 56 47 81

Website: www.sobi.com



PROFILE / DESCRIPTION of company:

About Sobi

Sobi is a pioneer in rare diseases. Our history of innovation in haemophilia treatments stretches over 50 years. We have the simple goal to provide people with haemophilia treatment choices that will help them live the lives they want. Sobi is launching Elocta® and Alprolix® (prescribing information are available on EMA website) across the region and it is our continued intent to make the treatments accessible to all.

Please visit: www.sobihaemophilia.com